
China approves Everest and Kezar lupus drug trial
SHANGHAI, China - Everest Medicines and Kezar Life Sciences (NASDAQ:KZR), Inc. have received approval from the Center for Drug Evaluation (CDE) of China\'s National Medical Products Administration (NMPA) to initiate a Phase 2b clinical trial for zetomipzomib, a treatment for lupus nephritis (LN), in China. The trial, named PALIZADE, will assess the efficacy and safety...